Genentech’s $2bn Holly Springs bet is taking shape, but the hardest manufacturing work is still ahead
Genentech’s $2 billion Holly Springs plant reaches a key milestone as Roche builds U.S. manufacturing capacity for future metabolic medicines.
Pharma & Biotech